Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 2, 2002, Pages 329-368

  Porter, John B ^a   Davis, Bernard A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiac function; Chelation therapy; Deferiprone monitoring tissue damage; Desferrioxamine; MRI; SQUID; Transfusional iron overload

Indexed keywords

ALPHA TOCOPHEROL; AMINOTRANSFERASE; ANTIARRHYTHMIC AGENT; APOLIPOPROTEIN E; ASCORBIC ACID; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DOBUTAMINE; ESTRADIOL; FERRITIN; FOLLITROPIN; GONADORELIN; HEMOGLOBIN; HEMOSIDERIN; HYDROCORTISONE; HYDROXYPYRIDINONE; IRON; IRON CHELATING AGENT; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; MALONALDEHYDE; PARATHYROID HORMONE; PENTETIC ACID; PYRIDONE DERIVATIVE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRANSFERRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ALBUMIN; APOLIPOPROTEIN E4; CALCIUM; CITRIC ACID; GLUCOSE; LYCOPENE; PHOSPHATE; THYROTROPIN; THYROXINE; VITAMIN D;

ADENOHYPOPHYSIS; ADOLESCENT; ADULT; AGRANULOCYTOSIS; CHELATION THERAPY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXCRETION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STABILITY; EVIDENCE BASED MEDICINE; EYE TOXICITY; FEMALE; FERRITIN BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; IRON OVERLOAD; IRON STORAGE; LABORATORY DIAGNOSIS; LIVER LEVEL; MALE; MEDICAL DECISION MAKING; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; OUTCOMES RESEARCH; PATIENT CARE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN MANIFESTATION; SURVIVAL RATE; THALASSEMIA; DRUG MONITORING; METABOLISM; METHODOLOGY; STANDARD; TREATMENT OUTCOME; ALZHEIMER DISEASE; ANAPHYLAXIS; ARTHRALGIA; ARTHROPATHY; BETA THALASSEMIA; BLOOD TRANSFUSION; BODY HEIGHT; BODY WEIGHT; BONE DEVELOPMENT; BONE DISEASE; BONE MARROW TRANSPLANTATION; BONE METABOLISM; BRAIN; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DNA POLYMORPHISM; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENDOCRINE FUNCTION; EXERCISE TEST; FEVER; GASTROINTESTINAL ABSORPTION; GLOMERULUS FILTRATION RATE; GLUCOSE TOLERANCE TEST; GLUCOSE URINE LEVEL; GONADORELIN TEST; GROWTH RETARDATION; HEART DISEASE; HEART FUNCTION; HEART MUSCLE; HEMOGLOBIN DETERMINATION; HUNTINGTON CHOREA; HYPOGONADOTROPIC HYPOGONADISM; HYPOPARATHYROIDISM; HYPOPHYSIS; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOTHYROIDISM; HYPOXIA; INFECTION RISK; IRON ABSORPTION; IRON BALANCE; IRON METABOLISM; KIDNEY DYSFUNCTION; LIVER BIOPSY; LUNG DISEASE; LUNG EMBOLISM; MACROPHAGE; MYALGIA; NEEDLE BIOPSY; NEUROIMAGING; NEUROTOXICITY; NEUTROPENIA; OSTEOPOROSIS; OXIDATIVE STRESS; PARATHYROID FUNCTION; PARKINSON DISEASE; PATIENT COMPLIANCE; SEXUAL DEVELOPMENT; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; THALASSEMIA MAJOR; THYROID FUNCTION; THYROXINE BLOOD LEVEL; TISSUE INJURY; URINARY EXCRETION; ZINC DEFICIENCY;

CHELATION THERAPY; DRUG MONITORING; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; THALASSEMIA; TREATMENT OUTCOME;

EID: 0036431540     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(02)90214-8     Document Type: Review

References (253)

1. Cohen A & Porter J. Transfusion and Iron Chelation Therapy in Thalassemia and Sickle Cell Anemia. Cambridge: Cambridge University Press, 2001.
2. Porter JB. Practical management of iron overload. British Journal of Haematology 2001; 115: 239-252.
3. Kushner JP, Porter JP & Olivieri NF. Secondary iron overload. Haematology 2001; 47-61.
4. Davis BA, O'Sullivan C & Porter JB. Survival in β-thalassaemia major: a single centre study. British Journal of Haematology 2001; 113 (supplement 1): 53. Abstract 201.
5. Modell B, Khan M & Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355: 2051-2052.
6. Modell B. Total management of thalassaemia major. Archives of Disease in Childhood 1977; 52: 485-500.
7. Thalassemia International Federation (TIF). Guidelines for Clinical Management of Thalassaemia. Nicosia. , Cyprus. TIF, 2000.
8. Graziano JH, Piomelli S, Hilgartner M et al. Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance. Journal of Pediatrics 1981; 99: 695-699.
9. Cazzola M, Borgra-Pignatti C, Locatelli F et al. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997; 37: 135-140.
10. Gordeuk VR, Bacon BR & Brittenham GM. Iron overload: causes and consequences. Annual Review of Nutrition 1987; 7: 485-508.
11. Pippard MJ, Callender ST, Warner GT & Weatherall DJ. Iron absorption and loading in beta-thalassaemia intermedia. Lancet 1979; ii: 819-821.
12. Pootrakul P, Kitcharoen K, Yansukon P et al. The effect of erythroid hyperplasia on iron balance. Blood 1988; 71: 1124-1129.
13. Fiorelli G, Fargion S, Piperno A et al. Iron metabolism in thalassemia intermedia. Haematologica 1990; 75 (supplement 5): 89-95.
14. Chuansumrit A, Hathirat P, Isarangkura P et al. Thrombotic risk of children with thalassemia. Journal of the Medical Association of Thailand 1993; 76 (supplement 2): 80-84.
15. Pootrakul P, Hungsprenges S, Fucharoen S et al. Relation between erythropoiesis and bone metabolism in thalassemia. New England Journal of Medicine 1981; 304: 1470-1473.
16. Hershko C. Determinants of fecal and urinary iron excretion in rats. Blood 1978; 51: 415-423.
17. Hershko C, Grady R & Cerami A. Mechanism of desferrioxamine-induced iron excretion in the hypertransfused rat: definition of two alternative pathways of iron mobilization. Journal of Laboratory and Clinical Medicine 1978; 92: 144-151.
18. Hershko C & Rachmilewitz E. Mechanism of desferrioxamine induced iron excretion in thalassaemia. British Journal of Haematology 1979; 42: 125-132.
19. Finch CA, Deubelbeiss K, Cook JD et al. Ferrokinetics in man. Journal of Clinical Investigation 1970; 49: 17-53.
20. Hershko C, Graham G, Bates GW & Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum fraction of potential toxicity. British Journal of Haematology 1978; 40: 255-263.
21. Porter JB, Abeysinghe RD, Marshall L et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996; 88: 705-713.
22. Hershko C, Cook J & Finch C. Storage iron kinetics III. Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells. Journal of Laboratory and Clinical Medicine 1973; 81: 876-886.
23. Saito K, Nishisato T, Grasso J & Aisen P. Interaction of transferrin with iron loaded rat peritoneal macrophages. British Journal of Haematology 1986; 62: 275-286.
24. Hershko C. A study of the chelating agent diethylenetriaminepentacetic acid using selective radioiron probes of reticuloendothelial and parenchymal iron stires. Journal of Laboratory and Clinical Medicine 1975; 85: 913-921.
25. Crichton R, Roman F & Roland F. Iron mobilisation from ferritin by chelating agents. Journal of Inorganic Biochemistry 1980; 13: 305-316.
26. Pippard MJ, Johnson DK & Finch CA. Hepatocyte iron kinetics in the rat explored with an iron chelator. British Journal of Haematology 1982; 52: 211-224.
27. Pippard M, Johnson D, Callender S & Finch C. Ferrioxamine excretion in iron loaded man. Blood 1982; 60: 288-294.
28. Modell CB & Beck J. Long term desferrioxamine therapy in thalassaemia. Annals of the New York Academy of Sciences 1974; 232: 201-210.
29. Sephton-Smith R. Iron excretion in thalassaemia major after administration of chelating agents. British Medical Journal 1962; 2: 1577-1580.
30. Pippard MJ, Callender ST & Weatherall DJ. Intensive iron-chelation therapy with desferrioxamine in iron-loading anaemias. Clinical Science and Molecular Medicine 1978; 54: 99-106.
31. Collins AF, Fassos FF, Stobie S et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (LI) in iron-loaded patients with sickle cell disease. Blood 1994; 83: 2329-2333.
32. Sergejew T, Forgiarini P & Schnebli HP. Chelator-induced iron excretion in iron-overloaded marmosets. British Journal of Haematology 2000; 110: 985-992.
33. Nisbet-Brown E, Olivieri N, Giardina P et al. A tridentate orally-active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron overloaded patients with thalassemia. Blood 2001; 98: 747a. Abstract 3111.
34. Pippard MJ. Desferrioxamine-induced iron excretion in humans. Baillière's Clinical Haematology 1989; 2: 323-343.
35. Letsky EA, Miller F, Worwood M & Flynn DM. Serum ferritin in children with thalassaemia regularly transfused. Journal of Clinical Pathology 1974; 27: 1213-1216.
36. Aldouri MA, Wonke B, Hoffbrand AV et al. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. Journal of Clinical Pathology 1987; 40: 1353-1359.
37. Olivieri NF. Long-term therapy with deferiprone. Acta Haematologica 1996; 95: 37-48.
38. Olivieri NF, Brittenham GM, Matsui D et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. New England Journal of Medicine 1995; 332: 918-922 (see comments).
39. Olivieri NF & Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-761 (see comments). Published erratum appears in Blood 1997;89:2621.
40. Lipschitz DA, Cook JD & Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. New England Journal of Medicine 1974; 290: 1213-1216.
41. Chapman RW, Hussain MA, Gorman A et al. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload. Journal of Clinical Pathology 1982; 35: 487-491.
42. Prieto J, Barry M & Sherlock S. Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology 1975; 68: 525-533.
43. Davis BA & Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95: 1229-1236.
44. Angelucci E, Brittenham GM, McLaren CE et al. Hepatic iron concentration and total body iron stores in thalassemia major. New England Journal of Medicine 2000; 343: 327-331.
45. Fischer R, Piga A, De Sanctis V et al. Large-scale study in thalassemia using biomagnetic liver susceptometry. Biomagnetometry 1998: Proceedings of the 11th International Conference on Biomagnetism. pp 1-4. Sendai, 1998.
46. Brownell A, Lowson S & Brozovic M. Serum ferritin concentration in sickle crisis. Journal of Clinical Pathology 1986; 39: 253-255.
47. Porter JB & Huehns ER. Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism. Acta Haematologica 1987; 78: 198-205.
48. Olivieri NF, Saxon BR, Nisbet-Brown E et al. Quantitive assessment of tissue iron in patients with sickle cell disease. Proceedings of the 9th International Conference on Oral Iron Chelation. p 55. Hamburg, Germany, 1999.
49. Hartmatz P, Quirolo K, Singer T et al. Development of hemochromatosis in patients with sickle cell disease (SCD) receiving chronic RBC transfusion therapy. Proceedings of the 9th International Conference on Oral Iron Chelation, p 54. Hamburg, Germany, 1999.
50. Olivieri NF, Nathan DG, MacMillan JH et al. Survival in medically treated patients with homozygous beta-thalassemia. New England Journal of Medicine 1994; 331: 574-578.
51. Davis B, O'Sullivan C & Porter J. Value of LVEF monitoring in the long-term management of beta-thalassaemia. Proceedings of the 8th International Conference on Thalassemia and the Hemoglobinopathies. p 147. Abstract 056. Athens., Greece, 2001.
52. Porter JB, Jaswon MS, Huehns ER et al. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. British Journal of Haematology 1989; 73: 403-409.
53. Modell B & Berdoukas V. The Clinical Approach to Thalassemia. New York: Grune and Stratton, 1981.
54. Barry M & Sherlock S. Measurement of liver-iron concentration in needle biopsy specimens. Lancet 1971; 1: 100-103.
55. Barry M, Flynn D, Letsky E & Risdon R. Long term chelation therapy in thalassaemia: effect on liver iron concentration, liver histology and clinical progress. British Medical Journal 1974; 2: 16-20.
56. Villeneuve JP, Bilodeau M, Lepage R et al. Variability in hepatic iron concentration measurement from needle-biopsy specimens. Journal of Hepatology 1996; 25: 172-177.
57. Angelucci E, Baronciani D, Lucarelli G et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. British Journal of Haematology 1995; 89: 757-761.
58. Emond MJ, Bronner MP, Carlson TH et al. Quantitative study of the variability of hepatic iron concentrations. Clinical Chemistry 1999; 45: 340-346.
59. Overmoyer BA, McLaren CE & Brittenham GM. Uniformity of liver density and nonheme (storage) iron distribution. Archives of Pathology and Laboratory Medicine 1987; 111: 549-554.
60. Brittenham GM, Farrell DE, Harris JW et al. Magnetic-susceptibility measurement of human iron stores. New England Journal of Medicine 1982; 307: 1671-1675.
61. Bauman JH & Harris JW. Estimation of hepatic iron stores by vivo measurement of magnetic susceptibility. Journal of Laboratory and Clinical Medicine 1967; 70: 246-257.
62. Brittenham GM, Zanzucchi PE, Farrell DE et al. Non-invasive in vivo measurement of human iron overload by magnetic susceptibility studies. Transactions of the Association of American Physicians 1980; 93: 156-163.
63. Nielsen P, Fischer R, Engelhardt R et al. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. British Journal of Haematology 1995; 91: 827-833.
64. Anderson L, Holden S, Davis B et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. European Heart Journal 2001; 22: 2171-2179.
65. Leung AW, Steiner RE & Young IR. NMR imaging of the liver in two cases of iron overload. Journal of Computer Assisted Tomography 1984; 8: 446-449.
66. Stark DD. Hepatic iron overload: paramagnetic pathology. Radiology 1991; 179: 333-335.
67. Brown DW, Henkelman RM, Poon PY & Fisher MM. Nuclear magnetic resonance study of iron overload in liver tissue. Magnetic Resonance Imaging 1985; 3: 275-282.
68. Worah D, Berger AE, Burnett KR et al. Ferrioxamine as a magnetic resonance contrast agent. Preclinical studies and phase I and II human clinical trials. Investigative Radiology 1988; 23 (supplement 1): S281-S285.
69. Vymazal J, Urgosik D & Bulte JW. Differentiation between hemosiderin- and ferritin-bound brain iron using nuclear magnetic resonance and magnetic resonance imaging. Cellular and Molecular Biology (Noisy-le-grand) 2000; 46: 835-842.
70. Kaltwasser JP, Gottschalk R, Schalk KP & Hartl W. Non-invasive quantitation of liver iron-overload by magnetic resonance imaging. British Journal of Haematology 1990; 74: 360-363.
71. Gomori JM & Grossman RI. The relation between regional brain iron and T2 shortening. American Journal of Neuroradiology 1993; 14: 1049-1050.
72. Jensen PD, Jensen FT, Christensen T & Ellegaard J. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. British Journal of Haematology 1994; 87: 171-184.
73. Liu P, Henkelman M, Joshi J et al. Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model. Canadian Journal of Cardiology 1996; 12: 155-164.
74. Engelhardt R, Langkowski JH, Fischer R et al. Liver iron quantification: studies in aqueous iron solutions, iron overloaded rats, and patients with hereditary hemochromatosis. Magnetic Resonance Imaging 1994; 12: 999-1007.
75. Allen PD, St Pierre TG, Chua-anusorn W et al. Low-frequency low-field magnetic susceptibility of ferritin and hemosiderin. Biochimica et Biophysica Acta 2000; 1500: 186-196.
76. Gandon Y, Guyader D, Heautot JF et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 1994; 193: 533-538.
77. Ernst O, Sergent G, Bonvarlet P et al. Hepatic iron overload: diagnosis and quantification with MR imaging. American Journal of Roentgenology 1997; 168: 1205-1208.
78. Bonkovsky HL, Rubin RB, Cable EE et al. Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. Radiology 1999; 212: 227-234.
79. Angelucci E, Giovagnoni A, Valeri G et al. Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood 1997; 90: 4736-4742.
80. Helpern JA, Ordidge RJ, Gorell JM et al. Preliminary observations of transverse relaxation rates obtained at 3 tesla from the substantia nigra of adult normal human brain. NMR in Biomedicine 1995; 8: 25-27.
81. Miszkiel KA, Paley MN, Wilkinson ID et al. The measurement of R2, R2* and R2′ in HIV-infected patients using the prime sequence as a measure of brain iron deposition. Magnetic Resonance Imaging 1997; 15: 1113-1119.
82. Siegelman ES. MR imaging of diffuse liver disease. Hepatic fat and iron. Magnetic Resonance Imaging Clinics of North America 1997; 5: 347-365.
83. Brittenham GM, Griffith PM, Nienhuis AW et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. New England Journal of Medicine 1994; 331: 567-573.
84. Telfer PT, Prestcott E, Holden S et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. British Journal of Haematology 2000; 110: 971-977.
85. Gabutti V & Piga A. Results of long term chelation therapy. Acta Haematologica 1996; 95: 26-36.
86. Fischer R. SQUID biomagnetic liver susceptibility in the adjustment of chelation therapy. S.O.S.T.E. Notiziario 2001; 2: 50-54 (11th International Conference on Oral Chelation in the Treatment of Thalassaemia and Other Diseases).
87. Zurlo MG, Stefano P, Borgna-Pignatti C et al. Survival and causes of death in thalassaemia major. Lancet 1989; ii: 27-30.
88. Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and disease complications in thalassemia major. Annals of the New York Academy of Sciences 1998; 850: 227-231.
89. Buja LM & Roberts WC. Iron in the heart. Etiology and clinical significance. American Journal of Medicine 1971; 51: 209-221.
90. Engle M. Cardiac involvement in Cooleys anemia. Annals of the New York Academy of Sciences 1964; 119: 694-702.
91. Kaufman KS, Papaefthymiou GC, Frankel RB & Rosenthal A. Nature of iron deposits on the cardiac walls in beta-thalassemia by Mossbauer spectroscopy. Biochimica et Biophysica Acta 1980; 629: 522-529.
92. St Pierre TG, Tran KC, Webb J et al. Organ-specific crystalline structures of ferritin cores in beta-thalassemia/hemoglobin E. Biology of Metals 1991; 4: 162-165.
93. Tran KC, Webb J, Macey DJ & Pootrakul P. Beta-thalassaemia/haemoglobin E tissue ferritins. II: a comparison of heart and pancreas ferritins with those of liver and spleen. Biology of Metals 1990; 3: 227-231.
94. Kyriacou K, Michaelides Y, Senkus R et al. Ultrastructural pathology of the heart in patients with beta-thalassaemia major. Ultrastructural Pathology 2000; 24: 75-81.
95. Marcus RE, Davies SC, Bantock HM et al. Desferrioxamine to improve cardiac function in iron overloaded patients with thalassaemia major. Lancet 1984; i: 392-393.
96. Kremastinos DT, Tiniakos G, Theodorakis GN et al. Myocarditis in beta-thalassemia major. A cause of heart failure. Circulation 1995; 91: 66-71.
97. Economou-Petersen E, Aessopos A, Kladi A et al. Apolipoprotein E epsilon4 allele as a genetic risk factor for left ventricular failure in homozygous beta-thalassemia. Blood 1998; 92: 3455-3459.
98. Kremastinos DT, Flevari P, Spyropoulou M et al. Association of heart failure in homozygous beta-thalassemia with the major histocompatibility complex. Circulation 1999; 100: 2074-2078.
99. Fitchett DH, Coltart DJ, Littler WA et al. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovascular Research 1980; 14: 719-724.
100. Barosi G, Arbustini E, Gavazzi A et al. Myocardial iron grading by endomyocardial biopsy. A clinicopathologic study on iron overloaded patients. European Journal of Haematology 1989; 42: 382-388.
101. Mavrogeni SI, Gotsis ED, Markussis V et al. T2 relaxation time study of iron overload in β-thalassemia. Magma 1998; 6: 7-12.
102. Jensen PD, Jensen FT, Christensen T et al. Indirect evidence for the potential ability of magnetic resonance imaging to evaluate the myocardial iron content in patients with transfusional iron overload. Magma 2001; 12: 153-166.
103. Papanikolaou N, Ghiatas A, Kattamis A et al. Non-invasive myocardial iron assessment in thalassaemic patients. T2 relaxometry and magnetization transfer ratio measurements. Acta Radiologica 2000; 41: 348-351.
104. Wielopolski L & Zaino EC. Noninvasive in-vivo measurement of hepatic and cardiac iron. Journal of Nuclear Medicine 1992; 33: 1278-1282.
105. Farquharson MJ, Bagshaw AP, Porter JB & Abeysinghe RD. The use of skin Fe levels as a surrogate marker for organ Fe levels, to monitor treatment in cases of iron overload. Physics in Medicine and Biology 2000; 45: 1387-1396.
106. Anderson L, Bunce N, Davis B et al. Reversal of siderotic cardiomyopathy: a prospective study with cardiac magnetic resonance. Heart 2001; 85 (supplement): .
107. Wonke B, Anderson L & Pennell D. Iron chelation treatment based on magnetic resonance imaging (MRI) in β-thalassaemia major. S.O.S.T.E Notiziario 2001; 2: 61-65 (11th International Conference on Oral Chelation in the Treatment of Thalassaemia and Other Diseases).
108. Chatterjee R, Katz M, Cox TF & Porter JB. Prospective study of the hypothalamic-pituitary axis in thalassaemic patients who developed secondary amenorrhoea. Clinical Endocrinology 1993; 39: 287-296.
109. Chatterjee R, Katz M, Oatridge A et al. Selective loss of anterior pituitary volume with severe pituitary-gonadal insufficiency in poorly compliant male thalassemic patients with pubertal arrest. Annals of the New York Academy of Sciences 1998; 850: 479-482.
110. Schenck JF. Imaging of brain iron by magnetic resonance: T2 relaxation at different field strengths. Journal of the Neurological Sciences 1995; 134 (supplement): 10-18.
111. Berg D, Hoggenmuller U, Hofmann E et al. The basal ganglia in haemochromatosis. Neuroradiology 2000; 42: 9-13.
112. Brooks DJ, Luthert P, Gadian D & Marsden CD. Does signal-attenuation on high-field T2-weighted MRI of the brain reflect regional cerebral iron deposition? Observations on the relationship between regional cerebral water proton T2 values and iron levels. Journal of Neurology, Neurosurgery and Psychiatry 1989; 52: 108-111.
113. Antonini A, Leenders KL, Meier D et al. T2 relaxation time in patients with Parkinson's disease. Neurology 1993; 43: 697-700.
114. Bartzokis G & Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingdon's disease. Cellular and Molecular Biology (Noisy-le-grand) 2000; 46: 821-833.
115. Metafratzi Z, Argyropoulou MI, Kiortsis DN et al. T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major. British Journal of Radiology 2001; 74: 407-410.
116. Berkovitch M, Bistritzer T, Milone SD et al. Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function. Journal of Pediatric Endocrinology and Metabolism 2000; 13: 179-184.
117. Argyropoulou MI, Metafratzi Z, Kiortsis DN et al. T2 relaxation rate as an index of pituitary iron overload in patients with beta-thalassemia major. American Journal of Roentgenology 2000; 175: 1567-1569.
118. Jessup M & Manno CS. Diagnosis and management of iron-induced heart disease in Cooley's anemia. Annals of the New York Academy of Sciences 1998; 850: 242-250.
119. Pantos C, Porter J, Huehns E & Walker J. Detection and implications of arrythmia in thalassaemia major. Proceedings of the 4th International Conference on Thalassemia and the Hemoglobinopathies. p 259. Nice, France, 1998.
120. Henry WL, Nienhuis AW, Wiener M et al. Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition. American Journal of Medicine 1978; 64: 547-555.
121. Giardina PJ, Ehlers KH, Engle MA et al. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study. Annals of the New York Academy of Sciences 1985; 445: 282-292.
122. Borow KM, Propper R, Bierman FZ et al. The left ventricular end-systolic pressure-dimension relation in patients with thalassemia major. A new noninvasive method for assessing contractile state. Circulation 1982; 66: 980-985.
123. Liu P, Henkelman M, Joshi J et al. Quantification of cardiac and tissue iron by nuclear magnetic resonance relaxometry in a novel murine thalassemia-cardiac iron overload model. Canadian Journal of Cardiology 1996; 12: 155-164.
124. Ehlers KH, Levin AR, Klein AA et al. The cardiac manifestations of thalassemia major: natural history, noninvasive cardiac diagnostic studies and results of cardiac catheterization. Cardiovascular Clinics 1981; 11: 171-186.
125. Nienhuis AW, Griffith P, Strawczynski H et al. Evaluation of cardiac function in patients with thalassemia major. Annals of the New York Academy of Sciences 1980; 344: 384-396.
126. Engle MA, Ehlers KH, O'Loughlin JE et al. Beta thalassemia and heart disease: three decades of gradual progress. Transactions of the American Clinical and Climatological Association 1984; 96: 24-33.
127. Lau KC, Li AM, Hui PW & Yeung CY. Left ventricular function in beta thalassaemia major. Archives of Disease in Childhood 1989; 64: 1046-1051.
128. Spirito P, Lupi G, Melevendi C & Vecchio C. Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. Circulation 1990; 82: 88-94.
129. Kremastinos DT, Toutouzas PK, Vyssoulis GP et al. Global and segmental left ventricular function in beta-thalassemia. Cardiology 1985; 72: 129-139.
130. Valdes-Cruz LM, Reinecke C, Rutkowski M et al. Preclinical abnormal segmental cardiac manifestations of thalassemia major in children on transfusion-chelation therapy: echographic alterations of left ventricular posterior wall contraction and relaxation patterns. American Heart Journal 1982; 103: 505-511.
131. Kremastinos DT, Toutouzas PK, Vyssoulis GP et al. Iron overload and left ventricular performance in beta thalassemia. Acta Cardiologica 1984; 39: 29-40.
132. Senior R, Batabyal SK, Dutta RN et al. An echo-cardiographic (M-mode & 2D) analysis of thalassaemia major. Indian Heart Journal 1990; 42: 73-76.
133. Intragumtornchai T, Minaphinant K, Wanichsawat C et al. Echocardiographic features in patients with beta thalassemia/hemoglobin E: a combining effect of anemia and iron load. Journal of the Medical Association of Thailand 1994; 77: 57-65.
134. Hou JW, Wu MH, Lin KH & Lue HC. Prognostic significance of left ventricular diastolic indexes in beta-thalassemia major. Archives of Pediatric and Adolescent Medicine 1994; 148: 862-866.
135. Leon MB, Borer JS, Bacharach SL et al. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. New England Journal of Medicine 1979; 301: 1143-1148.
136. Lewis BS, Lewis N, Dagan I et al. Studies of left-ventricular function in anemia due to beta-thalassemia. Israel Journal of Medical Sciences 1982; 18: 928-934.
137. Mariotti E, Agostini A, Angelucci E et al. Reduced left ventricular contractile reserve identified by low dose dobutamine echocardiography as an early marker of cardiac involvement in asymptomatic patients with thalassemia major. Echocardiography 1996; 13: 463-472.
138. Pili G, Bina P, Leoni G et al. Effect of the practice of sports on the cardiovascular system in thalassaemia major. Proceedings of the 8th International Conference on Thalassaemia and the Hemoglobinopathies. p 148. Abstract 057. Athens. , Greece. 2001.
139. Rozanski A, Diamond GA, Jones R et al. A format for integrating the interpretation of exercise ejection fraction and wall motion and its application in identifying equivocal responses. Journal of the American College of Cardiology 1985; 5: 238-248.
140. Angelides S, Freeman A, Berdoukas V et al. Dobutamine vs. bicycle exercise gated pool studies and thalassaemia. Proceedings of the 8th International Conference on Thalassaemia and the Hemoglobinopathies. p 146. Abstract 054. Athens. , Greece, 2001.
141. Freeman AP, Giles RW, Berdoukas VA et al. Early left ventricular dysfunction and chelation therapy in thalassemia major. Annals of Internal Medicine 1983; 99: 450-454.
142. Marcus RE, Davies SC, Bantock HM et al. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major. Lancet 1984; i: 392-393.
143. Freeman AP, Giles RW, Berdoukas VA et al. Sustained normalization of cardiac function by chelation therapy in thalassaemia major. Clinical and Laboratory Haematology 1989; 11: 299-307.
144. Aldouri MA, Wonke B, Hoffbrand AV et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematologica 1990; 84: 113-117.
145. Pfisterer M, Slutsky RA, Schuler G et al. Profiles of radionuclide left ventricular ejection fraction changes induced by supine bicycle exercise in normals and patients with coronary heart disease. Catheterization and Cardiovascular Diagnosis 1979; 5: 305-317.
146. Hecht HS, Karahalios SE, Ormiston JA et al. Patterns of exercise response in patients with severe left ventricular dysfunction: radionuclide ejection fraction and hemodynamic cardiac performance evaluations. American Heart Journal 1982; 104: 718-724.
147. Rumberger JA, Behrenbeck T, Bell MR et al. Determination of ventricular ejection fraction: a comparison of available imaging methods. The Cardiovascular Imaging Working Group. Mayo Clinic Proceedings 1997; 72: 860-870.
148. Aessopos A, Farmakis D, Karagiorga M et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97: 3411-3416.
149. Mariotti E, Angelucci E, Agostini A et al. Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. British Journal of Haematology 1998; 103: 916-921.
150. Landau H, Matoth I, Landau-Cordova Z et al. Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major. Clinical Endocrinology 1993; 38: 55-61.
151. Maurer HS, Lloyd-Still JD, Ingrisano C et al. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study. American Journal of Diseases of Children 1988; 142: 287-292.
152. Wang C, Tso SC & Todd D. Hypogonadotropic hypogonadism in severe beta-thalassemia: effect of chelation and pulsatile gonadotropin-releasing hormone therapy. Journal of Clinical Endocrinology and Metabolism 1989; 68: 511-516.
153. Shehadeh N, Hazani A, Rudolf MC et al. Neurosecretory dysfunction of growth hormone secretion in thalassemia major. Acta Paediatrica Scandinavica 1990; 79: 790-795.
154. Pintor C, Cella SG, Manso P et al. Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major. Journal of Clinical Endocrinology and Metabolism 1986; 62: 263-267.
155. Masala A, Meloni T, Gallisai D et al. Endocrine functioning in multitransfused prepubertal patients with homozygous beta-thalassemia. Journal of Clinical Endocrinology and Metabolism 1984; 58: 667-670.
156. Tolis G, Karydis I, Markousis V et al. Growth hormone release by the novel GH releasing peptide hexarelin in patients with homozygous beta-thalassemia. Journal of Pediatric Endocrinology and Metabolism 1997; 10: 35-40.
157. Leger J, Girot R, Crosnier H et al. Normal growth hormone (GH) response to GH-releasing hormone in children with thalassemia major before puberty: a possible age-related effect. Journal of Clinical and Endocrinology and Metabolism 1989; 69: 453-456.
158. Saenger P, Schwartz E, Markenson AL et al. Depressed serum somatomedin activity in beta-thalassemia. Journal of Pediatrics 1980; 96: 214-218.
159. Werther GA, Matthews R, Burger HG & Herington AC. Deficiency of non-suppressible insulin-like activity in thalassaemia major. Archives of Disease in Childhood 1981; 56: 855-859.
160. Bergeron C & Kovacs K. Pituitary siderosis. A histologic, immunocytologic, and ultrastructural study. American Journal of Pathology 1978; 93: 295-309.
161. Berkovitch M, Bistritzer T, Milone SD et al. Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function. Journal of Pediatric Endocrinology and Metabolism 2000; 13: 179-184.
162. Canale VC, Steinherz P, New M & Erlandson M. Endocrine function in thalassemia major. Annals of the New York Academy of Sciences 1974; 232: 333-345.
163. Bronspiegel-Weintrob N, Olivieri NF, Tyler B et al. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. New England Journal of Medicine 1990; 323: 713-719.
164. Italian Working Group on Endocrine Complications in non-Endocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassaemia major. Clinical Endocrinology 1995; 42: 581-586.
165. Jensen CE, Tuck SM, Old J et al. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. European Journal of Haematology 1997; 59: 76-81.
166. Karahanyan E, Stoyanova A, Moumdzhiev I & Ivanov I. Secondary diabetes in children with thalassaemia major (homozygous thalassaemia). Folia Medical 1994; 36: 29-34.
167. Soliman AT, el Banna N, al Salmi I & Asfour M. Insulin and glucagon responses to provocation with glucose and arginine in prepubertal children with thalassemia major before and after long-term blood transfusion. Journal of Tropical Pediatrics 1996; 42: 291-296.
168. Fosburg M & Nathan DG. Treatment of Cooleys anaemia. Blood 1990; 76: 435-444.
169. De Sanctis V, Stea S, Savarino L et al. Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine. Journal of Pediatric Endocrinology and Metabolism 1998; 11 (supplement 3): 827-833.
170. Gamberini MR, Fortini M, Gilli G et al. Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients. Journal of Pediatric Endocrinology and Metabolism 1998; 11 (supplement 3): 867-869.
171. Lassman MN, O'Brien RT, Pearson HA et al. Endocrine evaluation in thalassemia major. Annals of the New York Academy of Sciences 1974; 232: 226-237.
172. Flynn DM, Fairney A, Jackson D & Clayton BE. Hormonal changes in thalassaemia major. Archives of Disease in Childhood 1976; 51: 828-836.
173. Sabato AR, de Sanctis V, Atti G et al. Primary hypothyroidism and the low T3 syndrome in thalassaemia major. Archives of Disease in Childhood 1983; 58: 120-127.
174. Magro S, Puzzonia P, Consarino C et al. Hypothyroidism in patients with thalassemia syndromes. Acta Haematologica 1990; 84: 72-76.
175. Grundy RG, Woods KA, Savage MO & Evans JP. Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major. Archives of Disease in Childhood 1994; 71: 128-132.
176. Oberklaid F & Seshadri R. Hypoparathyroidism and other endocrine dysfunction complicating thalassaemia major. Medical Journal of Australia 1975; 1: 304-306.
177. McIntosh N. Endocrinopathy in thalassaemia major. Archives of Disease in Childhood 1976; 51: 195-201.
178. Costin G, Kogut MD, Hyman CB & Ortega JA. Endocrine abnormalities in thalassemia major. American Journal of Diseases of Childhood 1979; 133: 497-502.
179. Gertner JM, Broadus AE, Anast CS et al. Impaired parathyroid response to induced hypocalcemia in thalassemia major. Journal of Pediatrics 1979; 95: 210-213.
180. De Sanctis V, Vullo C, Bagni B & Chiccoli L. Hypoparathyroidism in beta-thalassemia major. Clinical and laboratory observations in 24 patients. Acta Haematologica 1992; 88: 105-108.
181. Pratico G, Di Gregorio F, Caltabiano L et al. La Pediatria Medica e Chirurgica 1998; 20: 265-268.
182. Livrea MA, Tesoriere L, Pintaudi AM et al. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood 1996; 88: 3608-3614.
183. Livrea MA, Tesoriere L, Maggio A et al. Oxidative modification of low-density lipoprotein and atherogenetic risk in beta-thalassemia. Blood 1998; 92: 3936-3942.
184. Houglum K, Ramm GA, Crawford DH et al. Excess iron induces hepatic oxidative stress and transforming growth factor beta I in genetic hemochromatosis. Hepatology 1997; 26: 605-610.
185. Hyman CB, Landing B, Alfin-Slater R et al. DI-alpha-tocopherol, iron, and lipofuscin in thalassemia. Annals of the New York Academy of Sciences 1974; 232: 211-220.
186. Rachmilewitz EA, Shifter A & Kahane I. Vitamin E deficiency in beta-thalassemia major: changes in hematological and biochemical parameters after a therapeutic trial with alpha-tocopherol. American Journal of Clinical Nutrition 1979; 32: 1850-1858.
187. De Luca C, Filosa A, Grandinetti M et al. Blood antioxidant status and urinary levels of catecholamine metabolites in beta-thalassemia. Free Radical Research 1999; 30: 453-462.
188. Nienhuis AW. Vitamin C and iron. New England Journal of Medicine 1981; 304: 170-171.
189. Davis B, O'Sullivan C & Porter J. Survival in beta-thalassaemia major is enhanced by specialist management. Proceedings of the 8th International Conference on Thalassemia and the Hemoglobinopathies. pp 117-118. Abstract 015. Greece. , Athens, 2001.
190. Araujo A, Kosaryan M, MacDowell A et al. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload. British Journal of Haematology 1996; 93: 835-837.
191. Piga A, Luzzatto L, Capalbo P et al. High dose desferrioxamine as a cause of growth failure in thalassaemic patients. European Journal of Haematology 1988; 40: 380-381.
192. Olivieri NF, Buncie JR, Chew E et al. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions. New England Journal of Medicine 1986; 314: 869-873.
193. Hoffbrand AV & Wonke B. Iron chelation therapy. Journal of Internal Medicine Supplement 1997; 740: 37-41.
194. Hoyes KP, Jones HM, Abeysinghe RD et al. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis. Experimental Haematology 1993; 21: 86-92.
195. Maclean KH, Cleveland JL & Porter JB. Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes. Blood 2001; 98: 3831-3839.
196. Kayyali R, Porter JB, Liu ZD et al. Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase. Journal of Biological Chemistry 2001; 276: 48814-48822.
197. Agarwal MB, Gupte SS, Viswanathan C et al. Long term assessment of efficacy and safety of LI, an oral iron chelator in transfusion dependent thalassaemia. British Journal of Haematology 1992; 82: 460-466.
198. Cragg L, Hebbel RP, Solovey A et al. The iron chelator LI potentiates iron-mediated oxidative DNA damage. Blood 1996; 88 (supplement 1): 646a (Abstract).
199. Davies SC, Marcus RE, Hungerford JL et al. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983; ii: 181-184.
200. Arden GB, Wonke B, Kennedy C & Huehns ER. Ocular changes in patients undergoing long term desferrioxamine treatment. British Journal of Ophthalmology 1984; 68: 873-877.
201. Rubinstein M, Dupont P, Doppee J et al. Ocular toxicity of desferrioxamine. Lancet 1985; i: 817-818.
202. Bournerias F, Monnier N, Dufier JL & Reveillaud RJ. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient]. Nephrologie 1987; 8: 27-29.
203. Pengloan J, Dantal J, Rossazza C et al. Ocular toxicity after a single intravenous dose of desferrioxamine in 2 hemodialyzed patients. Nephron 1987; 46: 211-212.
204. Blake DR, Winyard P, Lunec J et al. Cerebral and ocular toxicity induced by desferrioxamine. Quarterly Journal of Medicine 1985; 56: 345-355.
205. Polson R, Jawad A, Bomford A et al. Treatment of rheumatoid arthritis with desferrioxamine. Quarterly Journal of Medicine 1986; 61: 1153-1158.
206. Waxman H & Brown E. Clinical usefulness of iron chelating agents. Progress in Haematology 1969; 6: 338-373.
207. Duke-Elder S. Diseases of the Lens and Vitreous. St. Louis: CV Mosby, 1969.
208. Marsh MN, Holbrook IB, Clark C & Shaffer JL. Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine. Postgraduate Medical Journal 1981; 57: 582-584.
209. Guerin A, London G, Marchais S et al. Acute deafness and desferrioxamine. Lancet 1985; ii: 39-40.
210. Albera R, Pia F, Morra B et al. Hearing loss and desferrioxamine in homozygous beta-thalassemia. Audiology 1988; 27: 207-214.
211. Freedman MH, Bentur Y & Koren G. Biological and toxic properties of deferoxamine. Progress in Clinical and Biological Research 1989; 309: 115-124.
212. Wonke B, Hoffbrand AV, Aldouri M et al. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA. Archives of Disease in Childhood 1989; 64: 77-82.
213. Brill PW, Winchester P, Giardina PJ & Cunningham-Rundles S. Deferoxamine-induced bone dysplasia in patients with thalassemia major. American Journal of Roentgenology 1991; 156: 561-565.
214. Olivieri NF, Koren G, Harris J et al. Growth failure and bony changes induced by deferoxamine. American Journal of Pediatric Haematology and Oncology 1992; 14: 48-56.
215. De Virgillis S, Congia M, Frau F et al. Desferrioxamine-induced growth retardation in patients with thalassaemia major. Journal of Pediatrics 1988; 113: 661-669.
216. Rodda CP, Reid ED, Johnson S et al. Short stature in homozygous beta-thalassaemia is due to disproportionate truncal shortening. Clinical Endocrinology 1995; 42: 587-592.
217. Hartkamp MJ, Babyn PS & Olivieri F. Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients. Pediatric Radiology 1993; 23: 525-528.
218. Hatori M, Sparkman J, Teixeira CC et al. Effects of deferoximine on chondrocyte alkaline phosphatase activity: proxidant role of deferoximine in thalassemia. Calcified Tissue International 1995; 57: 229-236.
219. Caruso-Nicoletti M, De Sanctis V, Capra M et al. Short stature and body proportion in thalassaemia. Journal of Pediatric Endocrinology and Metabolism 1998; 11 (supplement 3): 811-816.
220. de Sanctis V, Stea S, Savarino L et al. Osteochondrodystrophic lesions in chelated thalassemic patients: an histological analysis. Calcified Tissue International 2000; 67: 134-140.
221. Orzincolo C, Castaldi G & Scutellari PN. Platyspondyly in treated beta-thalassemia. European Journal of Radiology 1994; 18: 129-133.
222. De Sanctis V, Pinamonti A, Di Palma A et al. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. European Journal of Pediatrics 1996; 155: 368-372.
223. Porter J, Singh S, Mohammed N et al. Osteopaenia in thalassaemia major: the relevance of desferrioxamine (DFO) metabolism. In: 24th Congress of the International Society of Haematology, p 47, Abstract 184. London: International Society of Haematology, 1992.
224. Porter JB, Faherty A, Stallibrass L et al. A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity. Annals of the New York Academy of Sciences 1998; 850: 483-487.
225. Miller KB, Rosenwasser LJ, Bessette JM et al. Rapid desenstitisation for desferrioxamine anaphylactic reaction. Lancet 1981; i: 1059 (Letter).
226. Bosquet J, Navarro M, Robert G et al. Rapid desensitisation for desferrioxamine anaphylactoid reaction. Lancet 1983; ii: 859-860.
227. Koren G, Bentur Y, Strong D et al. Acute changes in renal function associated with deferoxamine therapy. American Journal of Diseases of Children 1989; 143: 1077-1080.
228. Koren G, Kochavi Atiya Y, Bentur Y & Olivieri NF. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. International Journal of Haematology 1991; 54: 371-375.
229. Tenenbein M, Kowalski S, Sienko A et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 1992; 339: 699-701.
230. Freedman MH, Grisaru D, Olivieri N et al. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. American Journal of Diseases of Children 1990; 144: 565-569.
231. Levine JE, Cohen A, MacQueen M et al. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment. Journal of Pediatric Haematology and Oncology 1997; 19: 139-141.
232. Dickerhoff R. Acute aphasia and loss of vision with desferrioxamine overdose. Journal of Pediatric Haematology and Oncology 1987; 9: 287-288.
233. Walker JA, Sherman RA & Eisinger RP. Thrombocytopenia associated with intravenous desferrioxamine. American Journal of Kidney Disease 1985; 6: 254-256.
234. Robins-Browne R & Prpic J. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infection and Immunity 1985; 47: 774-779.
235. Li CK, Shing MM, Chik KW et al. Klebsiella pneumoniae meningitis in thalassemia major patients. Pediatric Haematology and Oncology 2001; 18: 229-232.
236. Wanachiwanawin W. Infections in E-beta thalassemia. Journal of Pediatric Haematology and Oncology 2000; 22: 581-587.
237. Hershko C & Hoffbrand AV. Iron chelation therapy. Reviews in Clinical and Experimental Haematology 2000; 4: 337-361.
238. Olivieri NF, Brittenham GM, McLaren CE et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New England Journal of Medicine 1998; 339: 417-423 (see comments).
239. Hoffbrand AV, Al-Refaie F, Davis B et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91: 295-300.
240. Cohen AR, Galanello R, Piga A et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. British Journal of Haematology 2000; 108: 305-312.
241. Hoffbrand A, Bartlett A, Veys P et al. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial. Lancet 1989; ii: 457.
242. al-Refaie FN, Wonke B, Hoffbrand AV et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (LI) in thalassemia major. Blood 1992; 80: 593-599 (see comments).
243. al-Refaie FN, Hershko C, Hoffbrand AV et al. Results of long-term deferiprone (LI) therapy: a report by the International Study Group on Oral Iron Chelators. British Journal of Haematology 1995; 91: 224-229.
244. Porter J, Hoyes K, Abeysinghe R et al. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and non-overloaded mice. Blood 1991; 78: 2727-2734.
245. al-Refaie FN, Wonke B & Hoffbrand AV. Deferiprone-associated myelotoxicity. European Journal of Haematology 1994; 53: 298-301.
246. Wonke B, Wright C & Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. British Journal of Haematology 1998; 103: 361-364 (see comments).
247. al-Refaie FN, Wonke B, Wickens DG et al. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine. Journal of Clinical Pathology 1994; 47: 657-660.
248. Mehta J, Singhal S, Revanker R et al. Fatal systemic lupus erythematosus in patient taking oral iron chelator LI. Lancet 1991; 337: 298. (Letter).
249. Berdoukas V, Bentley P, Frost H & Schnebli HP. Toxicity of oral chelator LI. Lancet 1993; 341: 1088. (Letter).
250. Chiodo AA, Alberti PW, Sher GD et al. Desferrioxamine ototoxicity in an adult transfusion-dependent population. Journal of Otolaryngology 1997; 26: 116-122.
251. Tondury P, Zimmermann A, Nielsen P & Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. British Journal of Haematology 1998; 101: 413-415.
252. Schwartz E, Wanless I, Sweeney G et al. Does deferiprone cause progressive hepatic fibrosis? In Proceedings of the 11th International Conference on Oral Chelation, p 36. Catania, Italy, 2001.
253. Olivieri NF, Rees DC, Ginder GD et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet 1997; 350: 491-492. (Letter).